We are live on ! Find out more
RGC icon

Regencell Bioscience
RGC

2 hedge funds and large institutions have $11.7K invested in Regencell Bioscience in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.06% less ownership

Funds ownership: 0.21% → 0.16% (-0.06%)

38% less capital invested

Capital invested by funds: $18.9K → $11.7K (-$7.17K)

50% less funds holding

Funds holding: 4 → 2 (-2)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
2
Holders Change
-2
Holders Change %
-50%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$102

Top Sellers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
-$5K
2
UBS Group
UBS Group
Switzerland
-$26
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
1
Morgan Stanley
New York
$6.53K +$102 +152 +1%
BlackRock
2
BlackRock
New York
$5.17K – – –
TRCT
3
Tower Research Capital (TRC)
New York
– -$5K -7,600 Closed
UBS Group
4
UBS Group
Switzerland
– -$26 -38 Closed

RGC Hedge Fund Activity: Q2 2023 in Review

2 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Regencell Bioscience (RGC) for Q2 2023, worth a combined $11.7K — down 38% from $18.9K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of RGC and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Morgan Stanley, adding an estimated $102. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $5K sold.

  • 2 institutional investors held Regencell Bioscience (RGC) as of Q2 2023, down from 4 in Q1 2023.
  • Funds reported $11.7K of Regencell Bioscience stock for Q2 2023, down 38% quarter-over-quarter.
  • 0 funds opened new Regencell Bioscience positions in Q2 2023 and 2 closed out, a net change of -2 holders.
  • The largest Regencell Bioscience buyer in Q2 2023 was Morgan Stanley, an estimated $102 added.
  • The largest Regencell Bioscience seller in Q2 2023 was Tower Research Capital (TRC), an estimated $5K sold.

Based on aggregated 13F filings for Q2 2023.